Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Optimal treatment of RAS mutated patients

Immunotherapy: MSI and beyond


10 Sep 2017


Optimal treatment of RAS mutated patients


Immunotherapy;  Colon and Rectal Cancer


Johanna Bendell


J.C. Bendell

Author affiliations

  • Medical Oncology, Sarah Cannon Research Institute and Tennessee Oncology, 37203 - Nashville/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.